Medical Condition News

RSS

AMS announces FDA clearance of MEVION S250 Proton Therapy System

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today shared a recent announcement from Mevion Medical Systems, Inc. regarding Mevion Medical Systems' receipt of FDA 510(k) clearance for its MEVION S250 Proton Therapy System.

12 Jun 2012

African-American survivors of prostate cancer have unmet psychosocial needs

Researchers at Moffitt Cancer Center have found that in African-American families where men are diagnosed with prostate cancer, they have unmet psychosocial needs that affect their survivorship, as well as family and social relationships.

12 Jun 2012

CRT, BioInvent partner to identify new therapeutic antibodies in oncology

BioInvent International AB and Cancer Research Technology Ltd (CRT), the commercial arm of Cancer Research UK, announced today that they have entered a collaboration with Queen Mary, University of London, to identify new therapeutic antibodies in oncology.

12 Jun 2012

Syapse introduces Discovery app to organize R&D data and processes

Syapse announced today the commercial launch of Discovery, its cloud-based application for making omics data actionable in clinical research and development. Discovery combines a powerful platform for aggregating and structuring biomedical data with intuitive data mining, workflow, and reporting features, enabling biopharma and diagnostics companies to leverage the increasing amount of data generated by advanced omics technologies such as next-generation sequencing.

12 Jun 2012

Aminoacyl-tRNA synthetases important targets for development of new drugs against major diseases

Researchers at the University of Gothenburg, Sweden, are working to develop substances that can prevent parasites, bacteria and fungi from producing essential proteins, research that could, in the long term, lead to new drugs for several major diseases.

12 Jun 2012

Sept. 11 compensation fund to cover cancer costs

A Sept. 11 compensation fund will cover the treatment of many different kinds of cancers -- at a cost of up to $147 million -- for people exposed to toxic material during and after the attacks.

12 Jun 2012

Researchers demonstrate effectiveness of a potential new therapy for stroke patients

Researchers at the University of Missouri have demonstrated the effectiveness of a potential new therapy for stroke patients in an article published in the journal Molecular Neurodegeneration. Created to target a specific enzyme known to affect important brain functions, the new compound being studied at MU is designed to stop the spread of brain bleeds and protect brain cells from further damage in the crucial hours after a stroke.

12 Jun 2012

Initial trial results from KYTHERA’s second of two Phase III trials with ATX-101

KYTHERA Biopharmaceuticals, Inc. today announced the presentation of initial trial results from Study ATX-101-10-17, the second of two pivotal European Phase III clinical trials with ATX-101, a facial injectable drug for the aesthetic treatment of submental fat, which commonly presents as an undesirable double chin.

12 Jun 2012

Australian CSIRO, GE Healthcare partner for investigational PET imaging agent

GE Healthcare today announced a collaboration with Australian Commonwealth Scientific and Industrial Research Organisation (CSIRO) involving its investigational PET imaging agent [18F flutemetamol].

12 Jun 2012

Genzyme files LEMTRADA sBLA and MAA with FDA, EMA for treatment of RMS

Genzyme, a Sanofi company, today announced that the company has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of LEMTRADA (alemtuzumab) for treatment of relapsing multiple sclerosis (RMS).

12 Jun 2012

Mindfulness can help cancer patients with anxiety and depression

When being diagnosed with cancer, people will naturally worry about their future, their family and about dying. Actually, no less than 35-40% of cancer patients suffer from significant anxiety and depression symptoms. An interdisciplinary research project carried out between Aarhus University, Business and Social Sciences and Aarhus University Hospital and the Danish Cancer Society now shows that mindfulness can help cancer those patients suffering from anxiety and depression.

12 Jun 2012

Study documents altruistic behavior by human embryonic stem cells

When most groups of mammalian cells are faced with a shortage of nutrients or oxygen, the phrase "every man for himself" is more apt than "all for one, one for all." Unlike colonies of bacteria, which often cooperate to thrive as a group, mammalian cells have never been observed to help one another out. But a new study led by a researcher at the Stanford University School of Medicine has shown that certain human embryonic stem cells, in times of stress, produce molecules that not only benefit themselves, but also help nearby cells survive.

12 Jun 2012

RGS proteins play an essential role in night blindness

In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have identified several proteins that help regulate cells' response to light-and the development of night blindness, a rare disease that abolishes the ability to see in dim light.

12 Jun 2012

Study shows how ruthenium-based drugs may be more effective at fighting cancer cells

A new study by University of Kentucky researchers shows how light and strained ruthenium-based drugs may be more effective at fighting cancer cells and less toxic to healthy cells than a similar and widely used drug.

12 Jun 2012

Researcher uncovers link between pro athlete's longevity and sleepiness

Coaches, owners and fantasy-league traders take note: Sleep researcher W. Christopher Winter, MD, has uncovered a link between a pro athlete's longevity and the degree of sleepiness experienced in the daytime.

12 Jun 2012

RVO advances PresbyLens into final phase of trial for treatment of presbyopia

ReVision Optics, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, announces the advancement of its proprietary product PresbyLens into the final phase of its U.S. clinical trial under an Investigational Device Exemption

12 Jun 2012

Individuals on statins more likely to experience fatigue with exertion

In a study of more than 1,000 adults, researchers at the University of California, San Diego, found that individuals taking cholesterol-lowering statin drugs are more likely than non-users to experience decreased energy, fatigue upon exertion, or both. The researchers suggest that these findings should be taken into account by doctors when weighing risk versus benefit in prescribing statins.

12 Jun 2012